# Composition for Treating Cirrhosis and Liver Cancer (SB-1121)

> **NCT05178303** · PHASE4 · COMPLETED · sponsor: **Nguyen Thi Trieu, MD** · enrollment: 134 (actual)

## Conditions studied

- Cirrhosis of the Liver

## Interventions

- **DRUG:** SB-1121(1)
- **DRUG:** SB-1121(2)

## Key facts

- **NCT ID:** NCT05178303
- **Lead sponsor:** Nguyen Thi Trieu, MD
- **Sponsor class:** INDIV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-30
- **Primary completion:** 2021-10-10
- **Final completion:** 2021-11-10
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178303, "Composition for Treating Cirrhosis and Liver Cancer (SB-1121)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05178303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*